Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Ubiquitin Ligases cIAP1 and cIAP2 Limit Cell Death to Prevent Inflammation.

Zhang J, Webster JD, Dugger DL, Goncharov T, Roose-Girma M, Hung J, Kwon YC, Vucic D, Newton K, Dixit VM.

Cell Rep. 2019 May 28;27(9):2679-2689.e3. doi: 10.1016/j.celrep.2019.04.111.

2.

RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases.

Patel S, Webster JD, Varfolomeev E, Kwon YC, Cheng JH, Zhang J, Dugger DL, Wickliffe KE, Maltzman A, Sujatha-Bhaskar S, Bir Kohli P, Ramaswamy S, Deshmukh G, Liederer BM, Fong R, Hamilton G, Lupardus P, Caplazi P, Lee WP, van Lookeren Campagne M, Johnson A, McKenzie BS, Junttila MR, Newton K, Vucic D.

Cell Death Differ. 2019 May 17. doi: 10.1038/s41418-019-0347-0. [Epub ahead of print]

PMID:
31101885
3.

Intrinsic apoptosis shapes the tumor spectrum linked to inactivation of the deubiquitinase BAP1.

He M, Chaurushiya MS, Webster JD, Kummerfeld S, Reja R, Chaudhuri S, Chen YJ, Modrusan Z, Haley B, Dugger DL, Eastham-Anderson J, Lau S, Dey A, Caothien R, Roose-Girma M, Newton K, Dixit VM.

Science. 2019 Apr 19;364(6437):283-285. doi: 10.1126/science.aav4902. Epub 2019 Apr 18.

PMID:
31000662
4.

Ubiquitin ligase COP1 coordinates transcriptional programs that control cell type specification in the developing mouse brain.

Newton K, Dugger DL, Sengupta-Ghosh A, Ferrando RE, Chu F, Tao J, Lam W, Haller S, Chan S, Sa S, Dunlap D, Eastham-Anderson J, Ngu H, Hung J, French DM, Webster JD, Bolon B, Liu J, Reja R, Kummerfeld S, Chen YJ, Modrusan Z, Lewcock JW, Dixit VM.

Proc Natl Acad Sci U S A. 2018 Oct 30;115(44):11244-11249. doi: 10.1073/pnas.1805033115. Epub 2018 Oct 15.

5.

OTULIN limits cell death and inflammation by deubiquitinating LUBAC.

Heger K, Wickliffe KE, Ndoja A, Zhang J, Murthy A, Dugger DL, Maltzman A, de Sousa E Melo F, Hung J, Zeng Y, Verschueren E, Kirkpatrick DS, Vucic D, Lee WP, Roose-Girma M, Newman RJ, Warming S, Hsiao YC, Kőműves LG, Webster JD, Newton K, Dixit VM.

Nature. 2018 Jul;559(7712):120-124. doi: 10.1038/s41586-018-0256-2. Epub 2018 Jun 27.

PMID:
29950720
6.

RIPK1 inhibits ZBP1-driven necroptosis during development.

Newton K, Wickliffe KE, Maltzman A, Dugger DL, Strasser A, Pham VC, Lill JR, Roose-Girma M, Warming S, Solon M, Ngu H, Webster JD, Dixit VM.

Nature. 2016 Dec 1;540(7631):129-133. doi: 10.1038/nature20559. Epub 2016 Nov 7.

PMID:
27819682
7.

RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.

Newton K, Dugger DL, Maltzman A, Greve JM, Hedehus M, Martin-McNulty B, Carano RA, Cao TC, van Bruggen N, Bernstein L, Lee WP, Wu X, DeVoss J, Zhang J, Jeet S, Peng I, McKenzie BS, Roose-Girma M, Caplazi P, Diehl L, Webster JD, Vucic D.

Cell Death Differ. 2016 Sep 1;23(9):1565-76. doi: 10.1038/cdd.2016.46. Epub 2016 May 13.

8.

β-Cell Insulin Secretion Requires the Ubiquitin Ligase COP1.

Suriben R, Kaihara KA, Paolino M, Reichelt M, Kummerfeld SK, Modrusan Z, Dugger DL, Newton K, Sagolla M, Webster JD, Liu J, Hebrok M, Dixit VM.

Cell. 2015 Dec 3;163(6):1457-67. doi: 10.1016/j.cell.2015.10.076. Epub 2015 Nov 25.

9.

Is SIRT2 required for necroptosis?

Newton K, Hildebrand JM, Shen Z, Rodriguez D, Alvarez-Diaz S, Petersen S, Shah S, Dugger DL, Huang C, Auwerx J, Vandenabeele P, Green DR, Ashkenazi A, Dixit VM, Kaiser WJ, Strasser A, Degterev A, Silke J.

Nature. 2014 Feb 27;506(7489):E4-6. doi: 10.1038/nature13024.

10.

Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis.

Newton K, Dugger DL, Wickliffe KE, Kapoor N, de Almagro MC, Vucic D, Komuves L, Ferrando RE, French DM, Webster J, Roose-Girma M, Warming S, Dixit VM.

Science. 2014 Mar 21;343(6177):1357-60. doi: 10.1126/science.1249361. Epub 2014 Feb 20.

PMID:
24557836
11.

Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.

Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, Bhakta S, Nguyen T, Dugger DL, Li G, Mai E, Lewis Phillips GD, Hiraragi H, Fuji RN, Tibbitts J, Vandlen R, Spencer SD, Scheller RH, Polakis P, Sliwkowski MX.

Clin Cancer Res. 2010 Oct 1;16(19):4769-78. doi: 10.1158/1078-0432.CCR-10-0987. Epub 2010 Aug 30.

12.

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX.

Cancer Res. 2008 Nov 15;68(22):9280-90. doi: 10.1158/0008-5472.CAN-08-1776.

13.

Synergistic induction of tumor antigens by Wnt-1 signaling and retinoic acid revealed by gene expression profiling.

Tice DA, Szeto W, Soloviev I, Rubinfeld B, Fong SE, Dugger DL, Winer J, Williams PM, Wieand D, Smith V, Schwall RH, Pennica D, Polakis P.

J Biol Chem. 2002 Apr 19;277(16):14329-35. Epub 2002 Feb 6.

14.

Overexpression of the retinoic acid-responsive gene Stra6 in human cancers and its synergistic induction by Wnt-1 and retinoic acid.

Szeto W, Jiang W, Tice DA, Rubinfeld B, Hollingshead PG, Fong SE, Dugger DL, Pham T, Yansura DG, Wong TA, Grimaldi JC, Corpuz RT, Singh JS, Frantz GD, Devaux B, Crowley CW, Schwall RH, Eberhard DA, Rastelli L, Polakis P, Pennica D.

Cancer Res. 2001 May 15;61(10):4197-205.

15.

Long-term erythropoietin expression in rodents and non-human primates following intramuscular injection of a replication-defective adenoviral vector.

Svensson EC, Black HB, Dugger DL, Tripathy SK, Goldwasser E, Hao Z, Chu L, Leiden JM.

Hum Gene Ther. 1997 Oct 10;8(15):1797-806.

PMID:
9358029
16.

Trace element concentrations in hair from autistic children.

Wecker L, Miller SB, Cochran SR, Dugger DL, Johnson WD.

J Ment Defic Res. 1985 Mar;29 ( Pt 1):15-22.

PMID:
4009700
17.
18.

Matastatic involvement of the heart in childhood rhabdomyosarcoma.

Pratt CB, Dugger DL, Johnson WW, Ainger LE.

Cancer. 1973 Jun;31(6):1492-7. No abstract available.

PMID:
4709964
19.

Treatment of pseudomonas infections in leukemic children with carbenicillin and colistin.

Pratt CB, Dugger DL.

Curr Ther Res Clin Exp. 1971 Mar;13(3):182-7. No abstract available.

PMID:
4998290

Supplemental Content

Loading ...
Support Center